Literature DB >> 29326298

Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years.

Surya P Bhatt1,2, Young-Il Kim3, Kathy F Harrington1, John E Hokanson4, Sharon M Lutz4, Michael H Cho5, Dawn L DeMeo5,6,7, James M Wells1,2, Barry J Make8, Stephen I Rennard9,10, George R Washko6,7, Marilyn G Foreman11, Donald P Tashkin12, Robert A Wise13, Mark T Dransfield1,2,14, William C Bailey1,2.   

Abstract

BACKGROUND: Cigarette smoking is the strongest risk factor for COPD. Smoking burden is frequently measured in pack-years, but the relative contribution of cigarettes smoked per day versus duration towards the development of structural lung disease, airflow obstruction and functional outcomes is not known.
METHODS: We analysed cross-sectional data from a large multicentre cohort (COPDGene) of current and former smokers. Primary outcome was airflow obstruction (FEV1/FVC); secondary outcomes included five additional measures of disease: FEV1, CT emphysema, CT gas trapping, functional capacity (6 min walk distance, 6MWD) and respiratory morbidity (St George's Respiratory Questionnaire, SGRQ). Generalised linear models were estimated to compare the relative contribution of each smoking variable with the outcomes, after adjustment for age, race, sex, body mass index, CT scanner, centre, age of smoking onset and current smoking status. We also estimated adjusted means of each outcome by categories of pack-years and combined groups of categorised smoking duration and cigarettes/day, and estimated linear trends of adjusted means for each outcome by categorised cigarettes/day, smoking duration and pack-years.
RESULTS: 10 187 subjects were included. For FEV1/FVC, standardised beta coefficient for smoking duration was greater than for cigarettes/day and pack-years (P<0.001). After categorisation, there was a linear increase in adjusted means FEV1/FVC with increase in pack-years (regression coefficient β=-0.023±SE0.003; P=0.003) and duration over all ranges of smoking cigarettes/day (β=-0.041±0.004; P<0.001) but a relatively flat slope for cigarettes/day across all ranges of smoking duration (β=-0.009±0.0.009; P=0.34). Strength of association of duration was similarly greater than pack-years for emphysema, gas trapping, FEV1, 6MWD and SGRQ.
CONCLUSION: Smoking duration alone provides stronger risk estimates of COPD than the composite index of pack-years. TRIAL REGISTRATION NUMBER: Post-results; NCT00608764. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  COPD epidemiology; emphysema; tobacco and the lung

Mesh:

Year:  2018        PMID: 29326298      PMCID: PMC5903957          DOI: 10.1136/thoraxjnl-2017-210722

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

Review 1.  Smoking behaviour and compensation: a review of the literature.

Authors:  G Scherer
Journal:  Psychopharmacology (Berl)       Date:  1999-07       Impact factor: 4.530

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Cigarette smoking and lung cancer: modeling total exposure and intensity.

Authors:  Jay H Lubin; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-03       Impact factor: 4.254

4.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

5.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Authors:  P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

6.  Measurement of self reported active exposure to cigarette smoke.

Authors:  J F Etter; T V Perneger
Journal:  J Epidemiol Community Health       Date:  2001-09       Impact factor: 3.710

7.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group.

Authors:  D P Tashkin; M D Altose; J E Connett; R E Kanner; W W Lee; R A Wise
Journal:  Am J Respir Crit Care Med       Date:  1996-06       Impact factor: 21.405

8.  Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II.

Authors:  W Dana Flanders; Cathy A Lally; Bao-Ping Zhu; S Jane Henley; Michael J Thun
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

9.  Smoking and lung function of Lung Health Study participants after 11 years.

Authors:  Nicholas R Anthonisen; John E Connett; Robert P Murray
Journal:  Am J Respir Crit Care Med       Date:  2002-09-01       Impact factor: 21.405

10.  Analysis of the lung microbiome in the "healthy" smoker and in COPD.

Authors:  John R Erb-Downward; Deborah L Thompson; Meilan K Han; Christine M Freeman; Lisa McCloskey; Lindsay A Schmidt; Vincent B Young; Galen B Toews; Jeffrey L Curtis; Baskaran Sundaram; Fernando J Martinez; Gary B Huffnagle
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

View more
  30 in total

1.  Early Chronic Obstructive Pulmonary Disease or Early Detection of Mild Disease?

Authors:  Surya P Bhatt
Journal:  Am J Respir Crit Care Med       Date:  2018-08-01       Impact factor: 21.405

2.  Effect of CSE on M1/M2 polarization in alveolar and peritoneal macrophages at different concentrations and exposure in vitro.

Authors:  Haoshen Feng; Yan Yin; Yuan Ren; Menglu Li; Dan Zhang; Mingtao Xu; Xu Cai; Jian Kang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2020-01-02       Impact factor: 2.416

3.  Both Duration and Pack-Years of Tobacco Smoking Should Be Used for Clinical Practice and Research.

Authors:  Roy A Pleasants; M Patricia Rivera; Stephen L Tilley; Surya P Bhatt
Journal:  Ann Am Thorac Soc       Date:  2020-07

4. 

Authors:  Samir Gupta
Journal:  Can Fam Physician       Date:  2022-06       Impact factor: 3.025

5.  Health-risk Behaviors and Type 1 Diabetes Outcomes in the Transition from Late Adolescence to Early Emerging Adulthood.

Authors:  Eunjin Lee Tracy; Cynthia A Berg; Ashley C Baker; Daniel Mello; Michelle L Litchman; Deborah J Wiebe
Journal:  Child Health Care       Date:  2018-10-22

6.  The clinical characteristics and outcomes of heart failure patient with chronic obstructive pulmonary disease from the Japanese community-based registry.

Authors:  Kensuke Takabayashi; Yuka Terasaki; Miyuki Okuda; Osamu Nakajima; Hitoshi Koito; Tetsuhisa Kitamura; Shouji Kitaguchi; Ryuji Nohara
Journal:  Heart Vessels       Date:  2020-08-07       Impact factor: 2.037

7.  Rural Residence and Poverty Are Independent Risk Factors for Chronic Obstructive Pulmonary Disease in the United States.

Authors:  Sarath Raju; Corinne A Keet; Laura M Paulin; Elizabeth C Matsui; Roger D Peng; Nadia N Hansel; Meredith C McCormack
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

Review 8.  More to Explore: Further Definition of Risk Factors for COPD - Differential Gender Difference, Modest Elevation in PM2.5, and e-Cigarette Use.

Authors:  Yixuan Zhang; Lu Wang; Gökhan M Mutlu; Hua Cai
Journal:  Front Physiol       Date:  2021-05-05       Impact factor: 4.566

9.  Association of Triglyceride-Glucose Index and Lung Health: A Population-Based Study.

Authors:  Tianshi David Wu; Ashraf Fawzy; Emily Brigham; Meredith C McCormack; Ivan Rosas; Dennis T Villareal; Nicola A Hanania
Journal:  Chest       Date:  2021-04-08       Impact factor: 10.262

10.  Effect of lung function disorders and physical activity on smoking and non-smoking students.

Authors:  Amelia Lorensia; Cynthia Marisca Muntu; Rivan Virlando Suryadinata; Roslin Septiani
Journal:  J Prev Med Hyg       Date:  2021-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.